Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Metrics to compare | 328130 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship328130PeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.4x | −3.9x | −0.6x | |
PEG Ratio | 0.20 | −0.11 | 0.00 | |
Price/Book | 7.7x | 2.6x | 2.6x | |
Price / LTM Sales | 16.6x | 5.8x | 3.2x | |
Upside (Analyst Target) | −31.2% | 10.1% | 41.8% | |
Fair Value Upside | Unlock | −7.1% | 5.1% | Unlock |